CONDYLINE

This brand name is authorized in Canada, Estonia, France, Ireland, Netherlands, New Zealand, Poland, Romania, UK.

Active ingredients

The drug CONDYLINE contains one active pharmaceutical ingredient (API):

1	Podophyllotoxin UNII L36H50F353 - PODOFILOX
	Podophyllotoxin is a metaphase inhibitor in dividing cells binding to at least one binding site on tubulin. Binding prevents tubulin polymerisation required for microtubule assembly. At higher concentrations, podophyllotoxin also inhibits nucleoside transport through the cell membrane.
	Read more about Podophyllotoxin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CONDYLINE Cutaneous solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D06BB04	Podophyllotoxin	D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BB Antivirals
Discover more medicines within D06BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	01945149
EE	Ravimiamet	1813812, 1831531
FR	Base de données publique des médicaments	61111385
GB	Medicines & Healthcare Products Regulatory Agency	38491
IE	Health Products Regulatory Authority	13209
NL	Z-Index G-Standaard	13184946
NL	Z-Index G-Standaard, PRK	72419
NZ	Medicines and Medical Devices Safety Authority	5378
PL	Rejestru Produktów Leczniczych	100015620, 100355071, 100358721, 100369825, 100437188
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66142001